Spoken word performer communicates plight of adults with ADHD who remain overlooked and unsupported.
Zug, Switzerland – October 24, 2016 – To mark ADHD Awareness Month, Shire plc (LSE: SHP, NASDAQ: SHPG) has today launched a powerful spoken word video to communicate the challenges many adults with Attention Deficit/Hyperactivity Disorder (ADHD) face in seeking accurate diagnosis and appropriate support.
Once thought of as a childhood problem, ADHD persists into adulthood in 50-66% of people diagnosed as a child 2,3,4,5 and affects around one in 30 (3.4%) adults worldwide.1 While many adults with ADHD lead happy and successful lives, ADHD can have a profound impact and has been linked to educational and occupational underachievement, poor quality of life, and difficulty in interpersonal, family and romantic relationships.6,7
“Some adults with ADHD suffer social stigma, delayed diagnosis or a lack of clear transition between adolescent and adult services,” said Tom Croce, Head of Global Patient Advocacy at Shire. “While every person with ADHD is an individual, with unique symptoms and needs, we hope this video will help to raise awareness of some of the issues many adults with ADHD face, so they can be provided with the support they need to take full control of their personal and professional lives.”
The video, entitled ‘The Truth’ is available to view on YouTube.
In a parallel initiative, ADHD Europe recently published an article about the shortage of transitional services for young adults, and a declaration stating the changes that need to be made to address this. Both can be found on www.adhdeurope.eu.
As a global leader in the development of medicines for treating ADHD, Shire is committed to working in partnership with healthcare professionals, health systems, patient advocacy organisations and other stakeholders to help people with ADHD, across all stages of life, tell their stories, and to help establish long-term solutions to improve the understanding, diagnosis and management of this life-altering condition.
ADHD is a neurodevelopmental disorder in children and adolescents8,9,10 and is recognised by the World Health Organization (WHO).11 Worldwide prevalence of ADHD is estimated to be between 5.29% and 7.1%, and just under 5% in Europe for children and adolescents (<18 years)8,9 and 3.4% (range 1.0-7.3%) for adults aged 18-44.1
|Deborah Hibbettemail@example.com||+41 41 288 4359|
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
2 Lara C, et al. Childhood Predictors of Adult Attention-Deficit/Hyperactivity Disorder: Results From The World Health Organization World Mental Health Survey Initiative. Biological Psychiatry 2009; 65:46-54.
4 Barklay RA, et al. The Persistence of Attention-Deficit/Hyperactivity Disorder into Young Adulthood as A Function of Reporting Source and Definition of Disorder. Journal of Abnormal Psychology 2002; 111:279-289.
10 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Available at https://www.psychiatry.org/psychiatrists/practice/dsm/dsm-5 [Last accessed October 2016].
11 International Classification of Diseases, 10th ed., (ICD-10). World Health Organization 2007:Chapter 5,F90. http://apps.who.int/classifications/icd10/browse/2010/en#/F90-F98. [Last accessed September 2016].